A
Alexander M.M. Eggermont
Researcher at Institut Gustave Roussy
Publications - 273
Citations - 40160
Alexander M.M. Eggermont is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Cancer & Melanoma. The author has an hindex of 73, co-authored 244 publications receiving 32056 citations. Previous affiliations of Alexander M.M. Eggermont include Erasmus University Rotterdam & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch,Jeffrey E. Gershenwald,Seng-Jaw Soong,John F. Thompson,Michael B. Atkins,David R. Byrd,Antonio C. Buzaid,Alistair J. Cochran,Daniel G. Coit,Shouluan Ding,Alexander M.M. Eggermont,Keith T. Flaherty,Phyllis A. Gimotty,John M. Kirkwood,Kelly M. McMasters,Martin C. Mihm,Donald L. Morton,Merrick I. Ross,Arthur J. Sober,Vernon K. Sondak +19 more
TL;DR: Revised melanoma staging system has been made that reflect the improved understanding of this disease and will be formally incorporated into the seventh edition of the AJCC Cancer Staging Manual and implemented by early 2010.
Journal ArticleDOI
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy,Bertrand Routy,Bertrand Routy,Lisa Derosa,Lisa Derosa,Lisa Derosa,Connie P.M. Duong,Connie P.M. Duong,Maryam Tidjani Alou,Maryam Tidjani Alou,Maryam Tidjani Alou,Romain Daillère,Romain Daillère,Romain Daillère,Aurélie Fluckiger,Aurélie Fluckiger,Meriem Messaoudene,Meriem Messaoudene,Conrad Rauber,Conrad Rauber,Conrad Rauber,Maria Paula Roberti,Maria Paula Roberti,Marine Fidelle,Marine Fidelle,Caroline Flament,Caroline Flament,Vichnou Poirier-Colame,Vichnou Poirier-Colame,Paule Opolon,Christophe Klein,Kristina Iribarren,Laura Mondragón,Nicolas Jacquelot,Nicolas Jacquelot,Nicolas Jacquelot,Bo Qu,Bo Qu,Bo Qu,Gladys Ferrere,Gladys Ferrere,Gladys Ferrere,Céline Clémenson,Céline Clémenson,Laura Mezquita,Jordi Remon Masip,C. Naltet,Solenn Brosseau,Coureche Kaderbhai,Corentin Richard,Hira Rizvi,Florence Levenez,Nathalie Galleron,Benoit Quinquis,Nicolas Pons,Bernhard Ryffel,Veronique Minard-Colin,Patrick Gonin,Jean-Charles Soria,Eric Deutsch,Eric Deutsch,Yohann Loriot,Yohann Loriot,François Ghiringhelli,Gérard Zalcman,François Goldwasser,B. Escudier,B. Escudier,Matthew D. Hellmann,Matthew D. Hellmann,Alexander M.M. Eggermont,Alexander M.M. Eggermont,Didier Raoult,Laurence Albiges,Laurence Albiges,Guido Kroemer,Laurence Zitvogel +76 more
TL;DR: It is found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition, and Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer.
Journal ArticleDOI
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vétizou,Marie Vétizou,Marie Vétizou,Jonathan M. Pitt,Jonathan M. Pitt,Jonathan M. Pitt,Romain Daillère,Romain Daillère,Romain Daillère,Patricia Lepage,Nadine Waldschmitt,Caroline Flament,Caroline Flament,Sylvie Rusakiewicz,Sylvie Rusakiewicz,Bertrand Routy,Maria Paula Roberti,Maria Paula Roberti,Connie P.M. Duong,Connie P.M. Duong,Vichnou Poirier-Colame,Vichnou Poirier-Colame,Antoine Roux,Antoine Roux,Antoine Roux,Sonia Becharef,Sonia Becharef,Silvia C. Formenti,Encouse B. Golden,Sascha Cording,Gérard Eberl,Andreas Schlitzer,Florent Ginhoux,Sridhar Mani,Takahiro Yamazaki,Takahiro Yamazaki,Nicolas Jacquelot,Nicolas Jacquelot,Nicolas Jacquelot,David Enot,David Enot,Marion Bérard,Jérôme Nigou,Jérôme Nigou,Paule Opolon,Alexander M.M. Eggermont,Alexander M.M. Eggermont,Paul Louis Woerther,Elisabeth Chachaty,Nathalie Chaput,Nathalie Chaput,Caroline Robert,Caroline Robert,Christina Mateus,Guido Kroemer,Didier Raoult,Ivo G. Boneca,Ivo G. Boneca,Franck Carbonnel,Mathias Chamaillard,Laurence Zitvogel +60 more
TL;DR: A key role is revealed for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade, which is found to depend on distinct Bacteroides species in mice and patients.
Journal ArticleDOI
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Jeffrey E. Gershenwald,Richard A. Scolyer,Kenneth R. Hess,Vernon K. Sondak,Georgina V. Long,M. I. Ross,Alexander J. Lazar,Mark B. Faries,John M. Kirkwood,Grant A. McArthur,Lauren E. Haydu,Alexander M.M. Eggermont,Keith T. Flaherty,Charles M. Balch,John F. Thompson +14 more
TL;DR: The melanoma staging system of the American Joint Committee on Cancer (AJCC) was updated in 2017 as discussed by the authors, with several important changes to the tumor, nodes, metastasis (TNM) classification and stage grouping criteria.
Journal ArticleDOI
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas,Igor Puzanov,Reinhard Dummer,Dirk Schadendorf,Omid Hamid,Caroline Robert,F. Stephen Hodi,Jacob Schachter,Anna C. Pavlick,Karl D. Lewis,Lee D. Cranmer,Christian U. Blank,Steven J. O'Day,Paolo A. Ascierto,April K.S. Salama,Kim Margolin,Carmen Loquai,Thomas Eigentler,Tara C. Gangadhar,Matteo S. Carlino,Sanjiv S. Agarwala,Stergios J. Moschos,Jeffrey A. Sosman,Simone M. Goldinger,Ronnie Shapira-Frommer,Rene Gonzalez,John M. Kirkwood,Jedd D. Wolchok,Alexander M.M. Eggermont,Xiaoyun Nicole Li,Wei Zhou,Adriane M Zernhelt,Joy Lis,Scot Ebbinghaus,S. Peter Kang,Adil Daud +35 more
TL;DR: In this article, the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma were compared.